Search

Your search keyword '"Kaarina Partanen"' showing total 113 results

Search Constraints

Start Over You searched for: Author "Kaarina Partanen" Remove constraint Author: "Kaarina Partanen" Language undetermined Remove constraint Language: undetermined
113 results on '"Kaarina Partanen"'

Search Results

1. Supplementary Figure 4 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

2. Supplementary Figure 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

3. Data from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

4. Supplementary Table 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

5. Supplementary Table 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

6. Supplementary Figure Legend from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

7. Supplementary Figure 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

8. Supplementary Table 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

9. Supplementary Figure 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

10. Supplementary Figure 5 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

11. Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients

12. [18F]-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography in Response Evaluation of Oncolytic Adenovirus Treatments of Patients with Advanced Cancer

13. Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

14. Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF

15. Hippocampus and entorhinal cortex in mild cognitive impairment and early AD

16. Long term outcome of temporal lobe epilepsy surgery: analyses of 140 consecutive patients

17. Patients with Acute Flank Pain: Comparison of MR Urography with Unenhanced Helical CT

18. Reproducibility of scoring emphysema by HRCT. Comparison of visual interpretation methods with pulmonary function tests among farmer's lung patients

19. VMAT technique enables concomitant radiotherapy of prostate cancer and pelvic bone metastases

20. PET/CT Dose Planning for Volumetric Modulated Arc Radiation Therapy (VMAT) -Comparison with Conventional Approach in Advanced Prostate Cancer Patients

21. Hippocampal and amygdaloid damage in partial epilepsy

22. MRI volumetry of the hippocampus, amygdala, entorhinal cortex, and perirhinal cortex after status epilepticus

23. [11C]Flumazenil binding in the medial temporal lobe in patients with temporal lobe epilepsy

24. Quantitative MRI volumetry of the entorhinal cortex in temporal lobe epilepsy

25. Verbal fluency activates the left medial temporal lobe: A functional magnetic resonance imaging study

26. Hippocampus in Alzheimer’s disease: a 3-year follow-up MRI study

27. Diagnosing fetal urinary tract abnormalities: benefits of MRI compared to ultrasonography

28. Quantitative MRI of the hippocampus and amygdala in severe depression

29. Diagnosing fetal urinary tract abnormalities: benefits of MRI compared to ultrasonography

30. Incremental cost‐effectiveness of double‐reading mammograms

31. Amygdala damage in experimental and human temporal lobe epilepsy

32. Long-term Risk of Emphysema in Patients with Farmer's Lung and Matched Control Farmers

33. Recurrent seizures may cause hippocambal damage in temporal lobe epilepsy

34. Placenta accreta: Imaging by gray-scale and contrast-enhanced color Doppler sonography and magnetic resonance imaging

35. Volumes of the Entorhinal and Perirhinal Cortices in Alzheimer’s Disease

36. MRI of the Hippocampus in Alzheimer’s Disease: Sensitivity, Specificity, and Analysis of the Incorrectly Classified Subjects

37. MRI volumetry and T2 relaxometry of the amygdala in newly diagnosed and chronic temporal lobe epilepsy

38. Cerebral blood flow changes associated with fetal intracranial hemorrhages

39. Lumbar disc herniations in children: a long-term clinical and magnetic resonance imaging follow-up study

40. Interobserver variability in measuring the dimensions of the abdominal aorta: Comparison of ultrasound and computed tomography

41. MR T2 relaxometry in Alzheimer's disease and age-associated memory impairment

42. Severity of hippocampal atrophy correlates with the prolongation of MRI T sub 2 relaxation time in temporal lobe epilepsy but not in Alzheimer's disease

43. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study

44. Frequency of Carotid Endarterectomy-Related Subclinical Cerebral Complications (Part 1 of 2)

45. Frequency of Carotid Endarterectomy-Related Subclinical Cerebral Complications (Part 2 of 2)

46. Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes

47. Hippocampal atrophy, acute THA treatment and memory in Alzheimerʼs disease

48. Abnormal regional benzodiazepine receptor uptake in the prefrontal cortex in patients with panic disorder

49. Late onset foot-drop muscular dystrophy with rimmed vacuoles

50. Reduced /V-acetylaspartate concentration in temporal lobe epilepsy by quantitative 1H MRS in vivo

Catalog

Books, media, physical & digital resources